ArticleLupus science & medicine2026
Systemic Lupus International Collaborating Clinics Frailty Index predicts mortality in systemic lupus erythematosus patients: data from the Almenara Lupus Cohort.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFrailty has been shown to predict damage accrual in patients with systemic lupus erythematosus (SLE), including those from Latin America. However, the impact of frailty on mortality has been scarcely evaluated, particularly in Latin American populations. The aim of this study was to evaluate frailty as a predictor of mortality in Latin American SLE patients.
methodsPatients from a single-centre 2012-2025 prevalent cohort were studied. Mortality was defined as the vital status according to the Peruvian Department of Health. Frailty was ascertained using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a continuous variable. Univariable and multivariable Cox regression models were done to estimate its impact on mortality. Multivariable models were adjusted for possible confounders. Sensitivity analyses were performed including data up to March 2020 to avoid the potential influence of the COVID-19 pandemic. Additionally, a Kaplan-Meier curve was calculated by frail status (frail, SLICC-FI >0.21; non-frail, SLICC-FI ≤0.21).
resultsFour hundred and ninety-five patients were included, 456 (92.1%) were women and 96 (19.4%) were frail. Their mean (SD) age at diagnosis was 35.0 (14.0) years, their mean disease duration at baseline was 6.7 (6.1) years and their mean follow-up time was 8.5 (4.2) years. Fifty-six (11.3%) patients died during the follow-up. The SLICC-FI predicted mortality even after adjusting for possible confounders (hazard ratio (HR)=1.54 (CI 95% 1.11 to 2.14), p=0.010). This prediction capability remained on the sensitivity analyses (HR 1.85; (95% CI 1.30 to 2.61), p<0.001).
conclusionFrailty, as ascertained with the SLICC-FI, was a predictor of mortality in a Latin American cohort of SLE patients. Frailty could be considered in the monitoring of SLE patients; possible interventions to modify it should be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.